Cargando…
Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study
BACKGROUND: Despite improvements in median survival some patients with advanced ovarian cancer die within 100 days of diagnosis; the reasons for which remain poorly understood. Here we investigate if ultra short-term survival can be explained by patient characteristics or treatment pathways. METHODS...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034099/ https://www.ncbi.nlm.nih.gov/pubmed/33832445 http://dx.doi.org/10.1186/s12885-021-08019-9 |
_version_ | 1783676481604419584 |
---|---|
author | Hawarden, Amy Russell, Bryn Gee, Mary Ellen Skayali, Fatima Clamp, Andrew Crosbie, Emma Jayne Edmondson, Richard John |
author_facet | Hawarden, Amy Russell, Bryn Gee, Mary Ellen Skayali, Fatima Clamp, Andrew Crosbie, Emma Jayne Edmondson, Richard John |
author_sort | Hawarden, Amy |
collection | PubMed |
description | BACKGROUND: Despite improvements in median survival some patients with advanced ovarian cancer die within 100 days of diagnosis; the reasons for which remain poorly understood. Here we investigate if ultra short-term survival can be explained by patient characteristics or treatment pathways. METHODS: A nested case comparison study was used to examine differences between patients with high grade serous ovarian/fallopian tube cancer who died within 100 days (n = 28) compared to a comparison group of patients matched for histology and including any survival greater than 100 days (n = 134). RESULTS: Cases and comparison patients had similar ages, BMI, ACE-27, deprivation indices, and distribution of disease on CT. There were no significant delays in time to diagnosis or treatment (p = 0.68) between the groups. However, cases had lower serum albumin, haemoglobin and higher platelet counts than matched comparison patients (p < 0.0001) and a worse performance score (P = 0.006). CONCLUSION: Patients who die rapidly after a diagnosis of ovarian cancer are only slightly older and have similar pre treatment frailty compared to patients whose survival approaches the median. However they do appear to undergo greater physiological compromise as a result of their disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08019-9. |
format | Online Article Text |
id | pubmed-8034099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80340992021-04-12 Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study Hawarden, Amy Russell, Bryn Gee, Mary Ellen Skayali, Fatima Clamp, Andrew Crosbie, Emma Jayne Edmondson, Richard John BMC Cancer Research Article BACKGROUND: Despite improvements in median survival some patients with advanced ovarian cancer die within 100 days of diagnosis; the reasons for which remain poorly understood. Here we investigate if ultra short-term survival can be explained by patient characteristics or treatment pathways. METHODS: A nested case comparison study was used to examine differences between patients with high grade serous ovarian/fallopian tube cancer who died within 100 days (n = 28) compared to a comparison group of patients matched for histology and including any survival greater than 100 days (n = 134). RESULTS: Cases and comparison patients had similar ages, BMI, ACE-27, deprivation indices, and distribution of disease on CT. There were no significant delays in time to diagnosis or treatment (p = 0.68) between the groups. However, cases had lower serum albumin, haemoglobin and higher platelet counts than matched comparison patients (p < 0.0001) and a worse performance score (P = 0.006). CONCLUSION: Patients who die rapidly after a diagnosis of ovarian cancer are only slightly older and have similar pre treatment frailty compared to patients whose survival approaches the median. However they do appear to undergo greater physiological compromise as a result of their disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08019-9. BioMed Central 2021-04-08 /pmc/articles/PMC8034099/ /pubmed/33832445 http://dx.doi.org/10.1186/s12885-021-08019-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Hawarden, Amy Russell, Bryn Gee, Mary Ellen Skayali, Fatima Clamp, Andrew Crosbie, Emma Jayne Edmondson, Richard John Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
title | Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
title_full | Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
title_fullStr | Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
title_full_unstemmed | Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
title_short | Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
title_sort | factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034099/ https://www.ncbi.nlm.nih.gov/pubmed/33832445 http://dx.doi.org/10.1186/s12885-021-08019-9 |
work_keys_str_mv | AT hawardenamy factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy AT russellbryn factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy AT geemaryellen factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy AT skayalifatima factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy AT clampandrew factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy AT crosbieemmajayne factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy AT edmondsonrichardjohn factorsdeterminingultrashorttermsurvivalandthecommencementofactivetreatmentinhighgradeserousovariancanceracasecomparisonstudy |